Takeda’s dengue vaccine shows promise in Phase III trial
TAK-003 is a tetravalent vaccine candidate based on a live-attenuated dengue serotype 2 virus. Credit: Bruno Glätsch from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more